



Recent Advances in Antiviral Drug Development

Guest Editor:

Dr. Natalie Borg

Head, Immunity and Immune Evasion Lab, School of Health and Biomedical Sciences, RMIT University, Bundoora 3083, Australia

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editor

Dear Colleagues,

Only around 3% of known human viral pathogens are able to be treated with Food and Drug Administration (FDA)-approved antivirals, and given these are mostly virus-targeted, drug resistance jeopardizes their efficacy. Further, the COVID-19 pandemic has highlighted major shortfalls and a lack of foresight in drug development against newly emerging viruses. This is why our ‘best’ option is to repurpose familiar drugs to treat COVID-19 patients. We urgently require new strategies to prevent and treat existing/emerging infections if we are to circumvent future significant health and economic global crises. This Special issue aims to give an overview of the most recent advances in antiviral drug development and new therapeutic targeting strategies.

Potential topics include but are not limited to:

- Antiviral drugs;
- Mechanisms of action;
- Perspectives for antiviral drug development;
- Future perspectives for newly emerging viruses;
- Host-targeted therapies;
- Identification of antiviral targets.

Dr. Natalie Borg

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma